

# Entheon Biomedical Engages Star Finance GmbH for Investor Relations

Vancouver, British Columbia--(Newsfile Corp. - January 12, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) ("**Entheon**" or the "**Company**"), a biotechnology company focused on developing psychedelic medicines to treat addiction, announces that it has entered into a consulting agreement (the "Agreement") with Star Finance GmbH ("Star Finance"), a Swiss-based company, to provide European investor relations services. Star Finance has offices in Steinhausen, Switzerland, and Cologne, Germany.

Star Finance is owned and operated by Michael Adams, who is a communications professional with more than 15 years of experience assisting Canadian public companies with introductions to investors, primarily in Germany and German-speaking Europe. Among other services, Star Finance owns and operates two established investment-focused financial websites and provides information about investment opportunities to its audience through e-mail newsletters, websites and various social media channels in the form of written articles as well as video content.

Under the terms of the Agreement, Star Finance will create and implement an investor relations program for the Company, assist in the organization and dissemination of Company information, and provide market intelligence services to the Company. In consideration of these services, the Company shall pay Star Finance EUR 24,000 for an initial 6-month term.

## **About Entheon Biomedical Corp.**

Entheon is a biotechnology research and development company committed to developing and commercializing a portfolio of safe and effective N,N-dimethyltryptamine based psychedelic therapeutic products ("**DMT Products**") for the purposes of treating addiction and substance use disorders. Subject to obtaining all requisite regulatory approvals and permits, Entheon intends to generate revenue through the sale of its DMT Products to physicians, clinics and licensed psychiatrists in the United States, certain countries in the European Union and throughout Canada.

## **On Behalf of the Board of Directors,**

"Timothy Ko"  
Timothy Ko, CEO

## **For more information, please contact:**

### **Entheon Biomedical Corp.**

Joseph Cullen, Investor Relations  
Telephone: +1 (778) 919-8615  
[joe@entheonbiomedical.com](mailto:joe@entheonbiomedical.com)  
<https://entheonbiomedical.com/>

## **For media inquiries, please contact Crystal Quast at:**

### **Bullseye Corporate**

Crystal Quast  
Telephone: +1 (647) 529-6364  
[Quast@BullseyeCorporate.com](mailto:Quast@BullseyeCorporate.com)

## **Cautionary Note on Forward-Looking Information**

*This news release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance.*

*All statements other than statements of historical fact may be forward-looking statements or information. The forward-looking statements and information are based on certain key expectations and assumptions made by management of the Company. Although management of the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward-looking statements and information since no assurance can be given that they will prove to be correct.*

*Forward-looking statements and information are provided for the purpose of providing information about the current expectations and plans of management of the Company relating to the future. Readers are cautioned that reliance on such statements and information may not be appropriate for other purposes, such as making investment decisions. Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. These include, but are not limited to, the Company's ability to raise further capital and the Company's ability to obtain regulatory and exchange approvals. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements and information contained in this news release are made as of the date hereof and no undertaking is given to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws. The forward-looking statements or information contained in this news release are expressly qualified by this cautionary statement.*

*Neither the CSE nor the Investment Industry Regulatory Organization of Canada accepts responsibility for the adequacy or accuracy of this release.*

**ENTHEON**

To view the source version of this press release, please visit  
<https://www.newsfilecorp.com/release/71871>